BioXcel Therapeutics, Inc. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
BioXcel Therapeutics, Inc. (BTAI) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $2.70 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-08-13
- 2026-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $2.70M.
- 2026-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $3.76M.
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $2.56M.
- 2025-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $3.03M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $3.76M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $2.56M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $3.03M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $3.47M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $3.87M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $4.21M 10-K · filed 2026-03-27 |
| 2024-09-30 | $2.06M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $2.17M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $2.26M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.08M 10-K · filed 2025-03-28 |
| 2023-09-30 | $7.32M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $7.70M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $8.05M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $8.39M 10-K · filed 2024-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |